Don’t market stem-cell products ahead of proof.
The controversy over an unproven stem-cell therapy in Italy highlights the dangers of doing translational medicine in reverse, argues Paolo Bianco. Nature 499, 255 (18 July 2013).
The controversy over an unproven stem-cell therapy in Italy highlights the dangers of doing translational medicine in reverse, argues Paolo Bianco. Nature 499, 255 (18 July 2013).